Computer simulations show higher benefit of lecanemab in males compared to females

Computational simulations using data from a Phase 3 trial of a potential new medication that may slow cognitive decline for people living with Alzheimer’s disease, lecanemab, showed that this medication is effective in males but also suggested no or limited effectiveness in females.

 

From: Andrews, D., Ducharme, S., Chertkow, H., Sormani, M.P., Collins, D.L. (2025) The higher benefit of lecanemab in males compared to females in CLARITY AD is probably due to a real sex effect. Alzheimer’s & Dementia; 21:e14467

Share

Published on April 16, 2025

CCNA - CCNV white logo

Receive the
latest news

Stay updated with the latest research developments from CCNA-CCNV. Our news section provides insights into cutting-edge studies, advancements in dementia care, and key findings in brain health research.

Illustration of elderly people on a park bench

You might be interested in...

  • May 20, 2025

    Save the date!

  • May 13, 2025

    Upcoming webinar – Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research

  • April 16, 2025

    CCNA is now accepting poster and Tik-Talk submissions for its annual conference in October 2025